← Back to Search

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

N/A
Recruiting
Led By Yuki Kimura, MD
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.

Eligible Conditions
  • Rheumatoid Arthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor
2,463 Previous Clinical Trials
2,961,547 Total Patients Enrolled
12 Trials studying Rheumatoid Arthritis
2,154 Patients Enrolled for Rheumatoid Arthritis
Childhood Arthritis and Rheumatology Research AllianceOTHER
3 Previous Clinical Trials
453 Total Patients Enrolled
Yuki Kimura, MDPrincipal InvestigatorHackensack Meridian Health
Laura Schanberg, MDPrincipal InvestigatorDuke Clinical Research Insitute
2 Previous Clinical Trials
9,708 Total Patients Enrolled
Timothy Beukelman, MD, MSCEPrincipal InvestigatorUniversity of Alabama at Birmingham
Mara L Becker, MD, MSCEPrincipal InvestigatorDuke Clinical Research Insitute
Mary Beth Son, MDPrincipal InvestigatorBoston Children's Hospital
~5290 spots leftby Jun 2028